LXRX Lexicon Corp: Price-to-Projected Revenue Ratio

The implementation of AI in molecule discovery is accelerating drug development for Lexicon Pharmaceuticals (LXRX). The forward P/S indicator on this GURU.Markets platform chart confirms this trend, with the metric currently standing at 20.60. High confidence among medical professionals is based on the efficacy of the company's drugs. Business protection relies on patents, although ultimate success depends on FDA verdicts regarding insurance reimbursements.

Lexicon Pharmaceuticals, Inc. - LXRX Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for Lexicon Corp (LXRX)

- market price and analyst price targets:

Price Chart Lexicon Pharmaceuticals, Inc.|LXRX - Average Forecast Price

- company stock capitalization data:

Market Value Lexicon Corp|LXRX - Total Company Value

- book value of equity indicators:

Book Value per Share Lexicon Pharmaceuticals|LXRX - Book Valuation of Business|Market Value to Book Value Ratio lexpharma.com|LXRX - Company Total Asset Base

- business debt structure and liquidity details:

- financial results and valuation multiples details:

LXRX - Net Financial Result|Projected Future Earnings Lexicon Pharmaceuticals|LXRX - Price to Earnings Ratio|Future Price to Earnings Lexicon Pharma|LXRX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|LXRX - Operating profit before amortization|Net earnings per share for the last 12 months Lexicon Pharmaceuticals|LXRX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months lexpharma.com|LXRX - Earnings per share trend in current year|Earnings growth forecast for next year Lexicon Pharmaceuticals

- sales volume and revenue indicators:

LXRX - Company Sales Revenue|Projected Sales Volume Lexicon Pharmaceuticals, Inc.|LXRX - P/S Multiple|Price-to-Projected Revenue Ratio Lexicon Corp

Summary company analytics:Lexicon Pharmaceuticals, Inc. LXRX

Original product of Lexicon Pharmaceuticals

Lexicon Pharmaceuticals' development of drugs for metabolic diseases is independent of economic cycles; therefore, the business value is determined solely by commercialization success and clinical data. This metric correlates current market capitalization with expected revenue, allowing the forward price-to-sales multiple chart to assess whether the company's shares are overbought relative to projected sales growth rates.

Competitor analysis

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Price-to-Projected Revenue Ratio Amicus Therapeutics FOLD|89bio.com - Price-to-Projected Revenue Ratio|Agios Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Structure Therapeutics Inc|MDXG (MiMedx Group) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue RZLT|MBX (MBX Biosciences Inc) - Forward P/S Multiple|altimmune.com (ALT) - Market Cap to Expected Sales Ratio|Forward P/S Multiple AARD|Forward Price-to-Revenue Multiple Sagimet Biosciences, Inc. SGMT|Price-to-Projected Revenue Ratio BioAge Labs Inc. BIOA|Biomea Fusion Corp (BMEA) - Market Cap to Future Revenue Ratio|QNCX - Price-to-Projected Revenue Ratio|GUTS (fractyl.com) - Market Cap to Projected Revenue|VTVT (vtvtherapeutics.com) - Forward Price-to-Revenue Multiple|Agape ATP - Forward Price to Sales|Price-to-Projected Revenue Ratio Pluristem Therapeutics|Synlogic Corp - Future Price to Revenue|Forward P/S Multiple LPCN|MTNB (matinasbiopharma.com) - Forward Price to Sales|Forward P/S Multiple SPRB (Spruce Biosciences, Inc.)|Forward P/S Multiple Galecto Inc GLTO|CTCX - Price-to-Projected Revenue Ratio|Forward Price to Sales LUMO (Lumos Therapeutics)|Organovo Holdings, Inc. (ONVO) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple radiuspharm.com